Evolent Health, Inc.
Simbolis: EVH
NYSE
31.93
USDRinkos kaina šiandien
-27.2314
P/E santykis
0.0238
PEG koeficientas
3.69B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Evolent Health, Inc. (EVH) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 677.41 | 192.8 | 188.2 | 266.3 | ||||||||||||
balance-sheet.row.short-term-investments | 118.9 | 13.8 | 14.5 | 75.7 | ||||||||||||
balance-sheet.row.net-receivables | 1480.17 | 446.7 | 254.7 | 130.6 | ||||||||||||
balance-sheet.row.inventory | -816.51 | 0 | -415.9 | -308.2 | ||||||||||||
balance-sheet.row.other-current-assets | 1020.3 | 30.3 | 451.1 | 435.3 | ||||||||||||
balance-sheet.row.total-current-assets | 2375.14 | 683.7 | 478.1 | 524 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 431.5 | 90.2 | 136.9 | 131.6 | ||||||||||||
balance-sheet.row.goodwill | 4469.59 | 1116.5 | 722.8 | 426.3 | ||||||||||||
balance-sheet.row.intangible-assets | 3157.46 | 752 | 442.8 | 279.8 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 7627.04 | 1868.6 | 1165.6 | 706.1 | ||||||||||||
balance-sheet.row.long-term-investments | 18.13 | 4.9 | 4.5 | 5.5 | ||||||||||||
balance-sheet.row.tax-assets | 25.53 | 12.1 | 0 | 39.4 | ||||||||||||
balance-sheet.row.other-non-current-assets | 108.87 | 20.9 | 32.3 | 13 | ||||||||||||
balance-sheet.row.total-non-current-assets | 8211.07 | 1996.6 | 1339.2 | 895.5 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 10586.21 | 2680.3 | 1817.3 | 1419.5 | ||||||||||||
balance-sheet.row.account-payables | 227.99 | 48.2 | 57.2 | 96.1 | ||||||||||||
balance-sheet.row.short-term-debt | 34.52 | 9.7 | 7.1 | 7.1 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 2596.52 | 635.1 | 469 | 273.4 | ||||||||||||
Deferred Revenue Non Current | 763.39 | 583.7 | 2.5 | 4.4 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 330.46 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 1593.18 | 610.3 | 363.4 | 330.4 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 3982.56 | 938.4 | 524.4 | 280.3 | ||||||||||||
balance-sheet.row.other-liabilities | 343.45 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 222.04 | 47.7 | 63.1 | 64.8 | ||||||||||||
balance-sheet.row.total-liab | 6207.46 | 1612.6 | 957.9 | 725.8 | ||||||||||||
balance-sheet.row.preferred-stock | 1695.41 | 178.4 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 345.76 | 1.2 | 1 | 0.9 | ||||||||||||
balance-sheet.row.retained-earnings | -2691.57 | -719.2 | -606.2 | -626.8 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -4.76 | -1.3 | -1.2 | -0.4 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5033.92 | 1608.6 | 1465.7 | 1319.9 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 4378.76 | 1067.7 | 859.4 | 693.6 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 10586.21 | 2680.3 | 1817.3 | 1419.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 4378.76 | 1067.7 | 859.4 | 693.6 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 10586.21 | - | - | - | ||||||||||||
Total Investments | 119.15 | 4.9 | 19 | 5.5 | ||||||||||||
balance-sheet.row.total-debt | 2626.43 | 644.8 | 476.1 | 280.5 | ||||||||||||
balance-sheet.row.net-debt | 1949.02 | 452 | 287.9 | 14.2 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -113.04 | -113 | -19.2 | -37.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 125.7 | 123.4 | 67.2 | 60 | |||||||||||
cash-flows.row.deferred-income-tax | -97.46 | -31.3 | 0.3 | -0.5 | |||||||||||
cash-flows.row.stock-based-compensation | 40.5 | 40.5 | 34 | 16.7 | |||||||||||
cash-flows.row.change-in-working-capital | 67.77 | 21.9 | -104.4 | -13.6 | |||||||||||
cash-flows.row.account-receivables | -164.69 | -164.7 | -103 | -5.8 | |||||||||||
cash-flows.row.inventory | 0 | -10.7 | 0 | -14.1 | |||||||||||
cash-flows.row.account-payables | -6.72 | -6.7 | 13.2 | 7.3 | |||||||||||
cash-flows.row.other-working-capital | 232.94 | 204.1 | -14.6 | -1 | |||||||||||
cash-flows.row.other-non-cash-items | 119.11 | 101.1 | 10.5 | 13.8 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 142.58 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -28.75 | -28.7 | -38.4 | -25 | |||||||||||
cash-flows.row.acquisitions-net | -388.25 | 0.9 | 5.6 | -34.8 | |||||||||||
cash-flows.row.purchases-of-investments | 387.45 | -0.9 | -5.6 | -3 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0.87 | 0.9 | 5.6 | 0.5 | |||||||||||
cash-flows.row.other-investing-activites | -387.74 | -387.7 | -226.3 | 46.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -415.54 | -415.5 | -259.1 | -15.8 | |||||||||||
cash-flows.row.debt-repayment | -464.47 | -464.2 | -219.7 | -98.8 | |||||||||||
cash-flows.row.common-stock-issued | 7.6 | 479.5 | 4.5 | 13.3 | |||||||||||
cash-flows.row.common-stock-repurchased | -15.29 | -15.3 | -18.3 | -3.9 | |||||||||||
cash-flows.row.dividends-paid | -18.79 | -18.8 | -14.9 | -1.3 | |||||||||||
cash-flows.row.other-financing-activites | 772.29 | 300.1 | 380 | 61.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 281.34 | 281.3 | 131.5 | -29.5 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.08 | -0.1 | -0.7 | -0.1 | |||||||||||
cash-flows.row.net-change-in-cash | 8.3 | 8.3 | -139.8 | -6.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 847.52 | 223.5 | 215.2 | 354.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 839.23 | 215.2 | 354.9 | 361.6 | |||||||||||
cash-flows.row.operating-cash-flow | 142.58 | 142.6 | -11.6 | 38.7 | |||||||||||
cash-flows.row.capital-expenditure | -28.75 | -28.7 | -38.4 | -25 | |||||||||||
cash-flows.row.free-cash-flow | 113.84 | 113.8 | -49.9 | 13.8 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1963.9 | 1963.9 | 1352 | 908 | ||||||||||||
income-statement-row.row.cost-of-revenue | 1503.43 | 1503.4 | 1035.4 | 657.6 | ||||||||||||
income-statement-row.row.gross-profit | 460.47 | 460.5 | 316.6 | 250.4 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 26.7 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 360.23 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34955.47 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 33.15 | -62.5 | 67.2 | 60 | ||||||||||||
income-statement-row.row.operating-expenses | 481.52 | 481.5 | 336.5 | 279.5 | ||||||||||||
income-statement-row.row.cost-and-expenses | 1984.95 | 1985 | 1371.9 | 937.1 | ||||||||||||
income-statement-row.row.interest-income | 5.26 | 5.3 | 1.4 | 0.4 | ||||||||||||
income-statement-row.row.interest-expense | 54.2 | 54.2 | 15.6 | 25.4 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34955.47 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -144.24 | -132.4 | -2.2 | -60 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 33.15 | -62.5 | 67.2 | 60 | ||||||||||||
income-statement-row.row.total-operating-expenses | -144.24 | -132.4 | -2.2 | -60 | ||||||||||||
income-statement-row.row.interest-expense | 54.2 | 54.2 | 15.6 | 25.4 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 58.49 | 123.4 | 67.2 | 60 | ||||||||||||
income-statement-row.row.ebitda-caps | 46.38 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -62.64 | -71.2 | -59.8 | 30.2 | ||||||||||||
income-statement-row.row.income-before-tax | -202.41 | -202.4 | -62.1 | -29.8 | ||||||||||||
income-statement-row.row.income-tax-expense | -89.36 | -89.4 | -43.4 | 0.5 | ||||||||||||
income-statement-row.row.net-income | -113.04 | -113 | -18.7 | -30.3 |
Dažnai užduodami klausimai
Kas yra Evolent Health, Inc. (EVH) bendras turtas?
Evolent Health, Inc. (EVH) bendras turtas yra 2680308000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 1067070000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.234.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 1.002.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.058.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.032.
Kas yra Evolent Health, Inc. (EVH) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -113040000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 644796000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 481525000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 192825000.000.